한국임상약학회지 (Korean Journal of Clinical Pharmacy)

  • 제28권2호
  • /
  • Pages.146-153
  • /
  • 2018
  • /
  • 1226-6051(pISSN)
  • /
  • 2508-786X(eISSN)
한국임상약학회 (Korean College Of Clinical Pharmacy)
권호 표지
DOI QR코드

DOI QR Code

다지역 임상시험의 계획 및 설계에 대한 국제 제도적 동향 분석

Regulations and Guidelines for Planning and Design of Multi-regional Clinical Trials

  • 송윤경 (서울대학교 약학대학, 종합약학연구소) ;
  • 손민지 (서울대학교 약학대학, 종합약학연구소) ;
  • 전아영 (서울대학교 약학대학, 종합약학연구소) ;
  • 김재현 (서울대학교 약학대학, 종합약학연구소) ;
  • 지은희 (가천대학교 약학대학) ;
  • 오정미 (서울대학교 약학대학, 종합약학연구소) ;
  • 김인화 (서울대학교 약학대학, 종합약학연구소)
  • Song, Yun-Kyoung (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Sohn, Minji (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Jeon, Ah Young (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Kim, Jae Hyun (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Ji, Eunhee (College of Pharmacy, Gachon University) ;
  • Oh, Jung Mi (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Kim, In-Wha (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University)
  • 투고 : 2017.12.06
  • 심사 : 2018.05.15
  • 발행 : 2018.06.29
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: Multi-regional clinical trials have been widely used for accelerating global drug development by multinational pharmaceutical companies. In this study, we aimed to review and analyze the international trends in regulations and guidelines on multi-regional clinical trials by regulatory authorities and international organizations, such as International Conference on Harmonisation, for referring to policies, including development of domestic guidelines for multi-regional clinical trials. Methods: The policies, regulations, and guidelines published by the US Food and Drug Administration, European Medicines Agency, Pharmaceuticals and Medical Devices Agency (Japan), and China Food and Drug Administration were searched, and the International Conference on Harmonisation E17 draft guideline was reviewed. Results: The regulatory authorities in developed countries have developed and implemented regulations and guidelines on multi-regional clinical trials to promote simultaneous global drug development and evaluate the regional differences in drug safety and efficacy. International Conference on Harmonisation developed the draft guideline for planning/designing of multi-regional clinical trials in 2016, which recommends the general principles for strategy-related issues and design of multi-regional clinical trials, and for protocol-related issues, such as consideration of regional variability, subject selection, dose selection, endpoints, comparators, overall sample size, allocation to regions, collecting information on efficacy and safety, and statistical analysis. Conclusion: It is important to understand the international regulatory requirements for designing and planning of multi-regional clinical trials for global drug development. Moreover, it is necessary to prepare multi-regional clinical trial guidelines in accordance with the Korean regulation for clinical trials and drug administration.

키워드

참고문헌

  1. $EvaluatePharma^{(R)}$. World Preview 2015, Outlook to 2020, 8th ed. Evaluate Ltd., 2015; 25.
  2. Shenoy P. Multi-regional clinical trials and global drug development. Perspect Clin Res 2016;7:62-7. https://doi.org/10.4103/2229-3485.179430
  3. MFDS, Analysis of approval status of '14 clinical trial; 607 in '$13{\rightarrow}652$ in '14. Osong. Ministry of Food and Drug Safety, 2015. Available from http://www.mfds.go.kr/index.do?x=23&searchkey=title:cotents&mid=675&searcword=14%B3%E2%20%C0%D3%BB%F3%BD%C3%C7%E8&y=3&division=&pageNo=1&seq=26363&sitecode=1&cmd=v. Accessed September 10, 2017
  4. Maeda H, Kurokawa T. Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan? Int J Clin Oncol 2015;20:1072-80. https://doi.org/10.1007/s10147-015-0825-4
  5. Yang H. Investigation on Multi-Regional Clinical Trial (MRCT). Regulatory Research on Food, Drug & Cosmetic 2014;9:149-57.
  6. Japan Pharmaceuticals and Medical Devices Agency. Basic principles on global clinical trials, Notification No.0928010. Available from https://www.pmda.go.jp/files/000157900.pdf. Accessed September 10, 2017
  7. Tanaka A, Asano K, Uyama Y. How should ethnicity-related information be included on drug labels? Considerations based on comparison of multiregional clinical trial data on the label between Japan and the United States. Clin Pharmacol Ther 2015;98:480-2. https://doi.org/10.1002/cpt.197
  8. Wang SJ. Multi-regional clinical trials-what are the challenges? Pharm Stat 2010;9:171-2.st https://doi.org/10.1002/pst.457
  9. ICH harmonised guideline - General principles for planning and design of multi-regional clinical trials E17 (draft). International Concil for Harmonisation. Available from http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E17/ICH_E17_draft_Step_1.pdf. Accessed September 10, 2017
  10. ICH harmonised guideline - General principles for planning and design of multi-regional clinical trials E17. International Concil for Harmonisation. Available from http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E17/E17EWG_Step4_2017_1116.pdf. Accessed April 30, 2018
  11. MFDS, Demonstrated the level of developed countries by regulating pharmaceuticals through ICH subscription; The sixth member of the regulatory body, including the United States, Europe, and Japan, Raise international credibility and expect pharmaceutical exports to activate. Osong, Ministry of Food and Drug Safety. Available from http://www.mfds.go.kr/index.do?x=38&searchkey=title:contents&mid=675&searchword=ICH&y=7&division=&pageNo=1&seq=34354&sitecode=1&cmd=v. Acce ssed September 10, 2017
  12. US Food and Drug Administration. Available from https://www.fda.gov. Accessed September 10, 2017
  13. European Medicines Agency. Available from http://www.ema.europa.eu/ema. Accessed September 10, 2017
  14. Ministry of Health, Labour and Welfare. Available from http://www.mhlw.go.jp/english. Accessed September 10, 2017
  15. Pharmaceuticals and Medical Devices Agency. Available from https://www.pmda.go.jp/english. Accessed September 10, 2017
  16. China Food and Drug Administration. Available from http://eng.sfda.gov.cn/WS03/CL0755. Accessed September 10, 2017
  17. International Concil for Harmonisation. Available from http://www.ich.org. Accessed September 10, 2017
  18. US Department of Health and Human Services, Food and Drug Administration. Strategy and implementation plan for advancing regulatory science for medical products. Available from https://www.fda.gov/downloads/RegulatoryInformation/LawsEnforcedbyFDA/SignificantAmendmentstotheFDCAct/FDASIA/UCM359956.pdf. Accessed September 10, 2017
  19. Chakravarty AG. Multi-regional clinical trials - considerations in design and analysis. In: Global drug development and its impact on CDER's drug review process symposium, Washington DC, USA, Jun 24, 2014.
  20. US Food and Drug Administration, CFR - Code of Federal Regulations Title 21. Available from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.106. Accessed September 10, 2017
  21. Guidance for Industry and Food and Drug Administration Staff - collection of race and ethnicity data in clinical trials. U.S. Department of Health and Human Services (HHS), Food and Drug Administration (FDA). Available from https://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126396.pdf. Accessed September 10, 2017
  22. European Commission DIRECTIVE 2001/20/EC, The European parliament and of the council of 4 April 2001. Available from https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2001_20/dir_2001_20_en.pdf. Accessed September 10, 2017
  23. Regulation (EC) No 726/2004 - Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. European Parliament and of the Council. Available from https://ec.europa.eu/health/ sites/health/files/files/eudralex/vol-1/reg_2004_726/ reg_2004_726_en.pdf. Accessed September 10, 2017
  24. Reflection paper on the extrapolation of results from clinical studies conducted outside of the EU to the EU population (EMEA/CHMP/EWP/692702/2008). European Medicines Agency. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/04/WC500125437.pdf. Accessed September 10, 2017
  25. Reflection paper on ethical and GCP aspects of clinical trials of medicinal products for human use conducted outside of the EU/EEA and submitted in marketing authorisation applications to the EU Regulatory Authorities (EMA/121340/2011). European Medicines Agency. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/04/WC7500125437.pdf. Accessed September 10, 2017
  26. Guideline on the investigation of subgroups in confirmatory clinical trials (EMA/CHMP/539146/2013). European Medicines Agency, 2014. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/02/WC500160523.pdf. Accessed September 10, 2017
  27. Jung YT. Generic drug evaluation analysis system of important export target country. Ministry of Food and Drug Safety. Available from http://www.riss.kr/search/detail/DetailView.do?p_mat_type=d7345961987b50bf&control_no=a305d09b08c8bbb8ffe0bdc3ef48d419. Accessed September 10, 2017
  28. Licensing Report Series -5: Japanese drug authorization system. APEC Harmonization Center. 2016.
  29. Basic principles on global clinical trials (reference cases). Japan Pharmaceuticals and Medical Devices Agency. Available from http://www.pmda.go.jp/files/000157520.pdf. Accessed September 10, 2017
  30. Basic principles for conducting phase I trials in the Japanese population prior to global clinical trials. Japan Pharmaceuticals and Medical Devices Agency. Available from http://www.pmda.go.jp/files/000157777.pdf. Accessed September 10, 2017
  31. Provisions for drug registration (SFDA Order No. 28). Chinese Food and Drug Administration. Available from http://eng.sfda.gov.cn/WS03/CL0768/61645.html. Accessed September 10, 2017
  32. Guidance for international multicenter clinical trials trial implementation. Chinese Food and Drug Administration. Available from http://www.sfda.gov.cn/WS01/CL1236/114002.html. Accessed September 10, 2017
  33. International Concil for Harmonisation. ICH harmonised guideline - Ethnic factors in the acceptability of foreign clinical data E5 (R1). Available from http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E5_R1/Step4/E5_R1__Guideline.pdf. Accessed April 30, 2018
  34. ICH Steering Committee. Final Concept Paper E17: General principle on planning/designing Multi-Regional Clinical Trials dated 21 May 2014. Available from http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html. Accessed September 10, 2017
  35. Ministry of Food and Drug Safety. Multiregional clinical trials' discussion. Available from http://www.nifds.go.kr/nifds/01_about/about08/about08_03d.jsp?mode=view&article_no=6175&pager.offset=0&board_no=55. Accessed April 30, 2018
  36. Korea National Enterprise for Clinical Trial. Available from https://www.konect.or.kr. Accessed April 30, 2018

피인용 문헌

  1. Perspectives on Adopting the Guideline for Multi-regional Clinical Trials in Korea: A Multi-stakeholder Survey vol.29, pp.4, 2019, https://doi.org/10.24304/kjcp.2019.29.4.267